Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

PreveCeutical Medical boosted as major pot group Aurora set to export cannabis to Australia for its research program

Tuesday, March 13, 2018 10:01
% of readers think this story is Fact. Add your two cents.

Health sciences group PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) has reached a major milestone for its Sol-Gel research program – receiving permits to allow cannabis to be imported into Australia.

The  flower and oils will be shipped from Canada by major pot group Aurora Cannabis Inc  (TSE:ACB) and used for the group’s drug delivery research program.

“We are extremely excited to receive the permits, allowing us to further our Sol-gel research program with the high quality cannabis products provided by Aurora,” said Stephen Van Deventer, chief executive and chairman of the group.

“The goal of the program is to cultivate a range of therapies that will benefit people with ailments such as epilepsy, pain and inflammation, safely and economically.”

Three permits were granted  by the Australian government, Department of Health. They were granted to the Pharmacy Australia Centre of Excellence (PACE) at the University of Queensland (UQ) .

The research is being conducted by PreveCeutical’s research partner UniQuest Pty Inc and led by PreveCeutical’s chief research officer Dr Harendra Parekh.

PreveCeutical aims to apply Sol-gel technology to cannabinoids to develop therapies for a range of symptoms, including pain, inflammation, seizures and neurological disorders.

The advantages of Sol-gels over conventional liquid nasal sprays include longer therapeutic effects, reduced dosages, and less irritation, the company noted.

For the shipment, Aurora has received certain rights, including the option to either license, on a non-exclusive basis, the technology for Canada and Australia, or to opt for a royalty arrangement on product sales, as well as to buy PreveCeutical shares.

“We see an important market for cannabis-based products that are more narrowly targeted at specific therapeutic areas but that are higher value add and being involved with initiatives such as PreveCeutical’s is part of our strategy to gain access to these types of products,” said Terry Booth, Aurora’s chief executive.

Aurora operates a 55,200 sq ft state-of-the-art production facility in Mountain View County, Alberta, known as ‘Aurora Mountain’, and a second 40,000 sq ft high-technology production facility known as ‘Aurora Vie’ in Pointe-Claire, Quebec on Montreal’s West Island.

In January this year,  Aurora’s 800,000 square foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed.

Once at full capacity, this is expected to produce over 100,000 kg a year of cannabis.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.